Diagnos Laboratorium Utama Tbk. vs Kian Santang Muliatama Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp224 (market cap 308B, 22.7K 24h volume), while Kian Santang Muliatama Tbk. trades at Rp212 (market cap 312.28B, 2.45M 24h volume). The key difference: Diagnos Laboratorium Utama Tbk. and Kian Santang Muliatama Tbk. are close in size by market cap, and Kian Santang Muliatama Tbk. is more actively traded (2.45M versus 22.7K). Which is the better fit depends on your goals.
| DGNS | RGAS | |
|---|---|---|
Market Cap | 308B | 312.28B |
Volume | 22.7K | 2.45M |
Lot | 227 | 24.54K |
Turnover | 5.17M | 518.29M |
Average Price | 227.59 | 211.19 |
Value | 5.17M | 518.29M |
Indicative Equilibrium Price | 230 | 214 |
Indicative Equilibrium Volume | 110 | 179.1K |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Kian Santang Muliatama Tbk (the Entity) was established based on the Notarial Deed of Artisa Khamelia Ramadiyanti, S.H., M.Kn., No. 634, dated November 28, 2018. The Entity started its commercial operations on 2019. The controlling party for the Company is Edy Nurhamid Amin.
Read more on RGAS →